Boron-containing small molecules as anti-inflammatory agents
Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
1. A method of treating an inflammatory-related disease in a human or an animal, said method comprising administering to the human or the animal a therapeutically effective amount of a compound having a structure according to Formula I:
wherein B is boron;
R 1a is a member selected from a negative charge, a salt counterion, H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
M is a member selected from oxygen, sulfur and NR 2a ;
R 2a is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
J is a member selected from (CR 3a R 4a ) n1 and CR 5a ;
R 3a , R 4a , and R 5a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
n1 is an integer selected from 0 to 2;
W is a member selected from C═O (carbonyl), (CR 6a R 7a ) m1 and CR 8a ;
R 6a , R 7a , and R 8a are members independently selected from H, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
m1 is an integer selected from 0 and 1;
A is a member selected from CR 9a and N;
D is a member selected from CR 10a and N;
E is a member selected from CR 11a and N;
G is a member selected from CR 12a and N;
R 9a , R 10a , R 11a and R 12a are members independently selected from H, OR*, NR*R**, SR*, —S(O)R*, —S(O) 2 R*, —S(O) 2 NR*R**, —C(O)R*, —C(O)OR*, —C(O)NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
wherein each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
the combination of nitrogens (A+D+E+G) is an integer selected from 0 to 3;
a member selected from R 3a , R 4a and R 5a and a member selected from R 6a , R 7a and R 8a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 3a and R 4a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 6a and R 7a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 9a and R 10a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 10a and R 11a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 11a and R 12a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
2. The method of claim 1 , further comprising administering said compound as part of a pharmaceutical formulation, said formulation further comprising a pharmaceutically acceptable excipient.
3. The method of claim 1 , wherein said compound has a structure according to:
4. The method of claim 3 , wherein said compound has a structure according to:
wherein
R 4a is a member selected from H, methyl, ethyl and substituted or unsubstituted aryl and substituted or unsubstituted arylalkyl;
R 10a is a member selected from H, halogen, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkoxy, substituted or unsubstituted arylthio and substituted or unsubstituted arylalkylthio; and
R 11a is a member selected from H, OH, methyl, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkoxy, substituted or unsubstituted arylthio and substituted or unsubstituted arylalkylthio.
5. The method of claim 4 , wherein said compound has a structure according to the following formula:
6. The method of claim 5 , wherein R 10a is a member selected from
wherein
R 15 is a member selected from CN, COOH and
R 16 and R 17 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
p is an integer selected from 1 to 5;
z is an integer selected from 1 to 8; and
X is a member selected from S and 0.
7. The method of claim 3 , wherein said compound has a structure according to:
wherein
R 4a is a member selected from substituted or unsubstituted aryl and substituted or unsubstituted arylalkyl;
R 10a is a member selected from H, halogen, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkoxy, substituted or unsubstituted arylthio and substituted or unsubstituted arylalkylthio.
8. The method of claim 6 , wherein said compound is a member selected from:
9. The method of claim 3 , wherein said compound is
10. The method of claim 3 , wherein said compound is a member selected from:
11. The method of claim 1 , wherein said compound is a member selected from:
12. The method of claim 3 , wherein R 1a is H.
13. The method of claim 3 , wherein R 10a and R 11a are H.
14. The method of claim 3 , wherein one member selected from R 10a and R 11a is H and the other member selected from R 10a and R 11a is a member selected from halogen, methyl, cyano, methoxy, hydroxymethyl and p-cyanophenyloxy.
15. The method of claim 3 , wherein R 10a and R 11a are members independently selected from fluoro, chloro, methyl, cyano, methoxy, hydroxymethyl, and p-cyanophenyl.
16. The method of claim 1 , wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.
17. The method of claim 1 , wherein the disease is a member selected from arthritis, rheumatoid arthritis, an inflammatory bowel disease, psoriasis, multiple sclerosis, a neurodegenerative disorder, congestive heart failure, stroke, aortic valve stenosis, kidney failure, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, a metabolic disease, a bone disease, a cardiovascular disease, a chemotherapy/radiation related complication, diabetes type I, diabetes type II, a liver disease, a gastrointestinal disorder, an ophthalmological disease, allergic conjunctivitis, diabetic retinopathy, Sjogren's syndrome, uveitis, a pulmonary disorder, a renal disease, dermatitis, HIV-related cachexia, cerebral malaria, ankylosing spondylitis, leprosy, anemia and fibromyalgia.
18. The method of claim 17 , wherein the neurodegenerative disorder is a member selected from Alzheimer's disease and Parkinson disease, the inflammatory bowel disease is a member selected from Crohn's disease or ulcerative colitis; the gastrointestinal complication is diarrhea; the liver disease is a member selected from an autoimmune hepatitis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis and fulminant liver failure; the gastrointestinal disorder is a member selected from celiac disease and non-specific colitis; the pulmonary disorder is a member selected from allergic rhinitis, asthma, chronic obstructive pulmonary disease, chronic granulomatous inflammation, cystic fibrosis, and sarcoidosis; the cardiovascular disease is a member selected from atheroscleotic cardiac disease, congestive heart failure and restenosis; and the renal disease is a member selected from glomerulonephritis and vasculitis.
19. The method of claim 1 , wherein the compound is administered at a concentration sufficient to inhibit a cytokine which is a member selected from IL-1α, β, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF-α, LT, LIF, Oncostatin, and IFNc1α, β, γ.
20. The method of claim 1 , where the compound is administered at a concentration sufficient to stimulate expression of a cytokine which is a member selected from IL-4, IL-10, IL-11, W-13 and TGF-β.
21. A method of treating an inflammatory-related disease associated with cytokine expression levels, which comprises administering to a human or an animal in need of such treatment the compound of claim 1 .
22. Inc method of claim 1 , wherein the compound is in an amount sufficient to treat the inflammatory-related disease by inhibiting pro-inflammatory cytokine expression or by stimulating anti-inflammatory cytokine expression, but the amount is less than sufficient to substantially inhibit cyclin dependent kinases.
23. The method of claim 1 , wherein the animal is a human being.
24. A method for inhibiting the production of an inflammatory cytokine protein by cells capable of producing said inflammatory cytokine protein, said method comprising: combining said cells with a therapeutic amount of the compound of claim 1 , wherein production of said inflammatory cytokine by said cells is inhibited.
25. The method according to claim 24 , wherein said therapeutic amount is sufficient to inhibit the production of said inflammatory cytokine protein between about 50% and about 99%.
26. A method for inhibiting an inflammatory response in a human or an animal, said method comprising: contacting said human or animal with a therapeutic amount of the compound of claim 1 , wherein said inflammatory response is inhibited.
27. A method of treating an inflammatory-related disease in a human or an animal, said method comprising administering to the human or the animal a therapeutically effective amount of a compound having a structure according to Formula II:
wherein
B is boron;
R 20 , R 21 and R 22 are members independently selected from a negative charge, a salt counterion, H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
A is a member selected from CR 9a and N;
D is a member selected from CR 10a and N;
E is a member selected from CR 11a and N;
G is a member selected from CR 12a and N;
wherein
R 9a , R 10a , R 11a and R 12a are members independently selected from H, OR*, NR*R**, SR*, —S(O)R*, —S(O) 2 R*, —S(O) 2 NR*R**, —C(O)R*, —C(O)OR*, —C(O)NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
wherein each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
wherein
R 9a and R 10a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring;
R 10a and R 11a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring; and
R 11a and R 12a , together with the atoms to which they are attached, are optionally joined to form a 4 to 7 membered ring.
28. The method of claim 27 , wherein said compound has a structure according to:
29. The method of claim 27 , wherein said compound is a member selected from: